세계 간질환 치료제 시장은 2025-2032년의 예측 기간 동안 7.11%의 연평균 복합 성장률(CAGR)을 나타내고, 2024년 256억 7,000만 달러에서 2032년 444억 7,000만 달러로 성장할 것으로 예측됩니다. 간질환 치료제 시장은 빠르게 발전하고 있습니다. 이는 건강에 해로운 식습관, 음주, 비만 증가로 인해 간염, 지방간, 간경화 등 간 질환의 발병률이 증가하고 있는 것이 주요 원인입니다. 검진 프로그램의 개선으로 많은 환자들이 조기에 진단을 받을 수 있게 되었고, 치료 접근성도 향상되었습니다. 제약회사의 R&D 비용은 지속적으로 증가하고 있으며, 새로운 효과적인 치료법에 대한 접근성이 높아지면서 시장 성장에 힘을 실어주고 있습니다. 진단의 발전과 침습적 검사를 필요로 하지 않는 표적 치료의 가용성은 빠르게 증가하고 있으며, 새로운 기회를 창출하고 있습니다. 각국 정부는 간 질환의 조기 진단과 예방을 위한 공중보건 후속 조치와 인식 제고에 투자하고 있습니다.
제약회사들도 연구개발에 대한 투자를 늘리고 있으며, 새로운 효과적인 치료법을 시장에 출시할 수 있는 가능성을 높이고 있습니다. 또한, 전자 약국 및 보다 쉽게 이용할 수 있게 된 관련 의료로 인해 필요한 약물 치료에 대한 접근성이 향상되고 있습니다. 전반적으로 수요는 강하고, 기술 혁신이 계속되고, 정부 정책도 계속 시장을 지지할 것으로 보입니다. 위의 요인들은 앞으로도 시장 성장을 뒷받침할 것으로 보입니다.
예를 들어, 2025년 4월 인도 연방 내무부 장관이 인도 간담췌장과학연구소(ILBS)가 실시한 '세계 간의 날' 프로그램에서 강연을 통해 간 건강에 대한 인식과 HEALED 제도와 같은 프로그램의 필요성을 지적하고 국가 전체의 인식을 촉진했습니다. 또 다른 예로, 2025년 4월, 인도 연방 보건부 장관은 FSSAI 및 인도 간 담도 과학 연구소와 공동으로 주최한 건강 캠프에서 간 건강에 대한 서약식을 주도했습니다.
대상이 되는 모든 지역과 국가에 대해 모든 부문이 제공됩니다.
위에 언급된 회사는 시장 점유율에 따른 순위를 보유하지 않으며, 조사 작업 중 이용 가능한 정보에 따라 변경될 수 있습니다.
Global liver disease therapeutics market is projected to witness a CAGR of 7.11% during the forecast period 2025-2032, growing from USD 25.67 billion in 2024 to USD 44.47 billion in 2032. The liver disease therapeutics market continues to develop at a rapid rate. This development is largely attributed to the increasing incidence of liver disease including hepatitis, fatty liver and cirrhosis due to the growing rate of unhealthy diets, alcohol consumption, and obesity. Many patients are diagnosed earlier due to better screening programs increasing their access to treatment rights away. The R&D spending from pharmaceutical companies continues to increase and is in part driving growth of the market due to increased access to new, effective therapy options. The advances in diagnostics and the availability of targeted therapies that do not require invasive testing are increasing rapidly and creating new opportunities. Governments are investing in public health follow-up and awareness of liver disease which leads to early diagnosis and prevention of liver disease.
Pharmaceutical companies are also investing more in research and development which enhances the prospect of bringing forward new effective therapies to the market. Additionally, e-pharmacies and more accessible allied health care provide better access to needed drug therapies. Overall, demand is strong, there is continued innovation, and government policies will continue to support the market. The above factors will continue to support the growth of the market.
For instance, in April 2025, Indian Union Home Minister spoke at a World Liver Day program conducted by the Institute of Liver and Biliary Sciences (ILBS) in India and noted the need for liver health recognition and programs, such as the HEALED scheme, to promote countrywide awareness. In another instance, in April 2025, Indian Union Health Minister led a Liver Health Pledge Ceremony during a health camp organized by the Ministry in collaboration with FSSAI and the Institute of Liver and Biliary Sciences, In India.
Impact of Unhealthy Lifestyles on the Rising Prevalence of Liver Diseases
Liver diseases are rising worldwide as people continue to follow poor lifestyle habits. The combination of sedentary habits and a diet that has high saturated fats and sugar is a big part of the epidemic rise of non-alcoholic fatty liver disease (NAFLD) and its potential for progression. High alcohol consumption is still one of the biggest players in the development of alcoholic liver disease and thus cirrhosis. Smoking and drug use can also worsen liver injury, which commonly leads to obesity, along with insulin resistance and metabolic syndrome, a major risk factors for chronic liver disease. With the increasing prevalence of lifestyle habits across urban populations, liver disease prevalence will continue to increase alongside lifestyle diseases. It is going to require coordinated public health action for prevention, early diagnosis, and treatment of disease.
For instance, in 2023, the National Vital Statistics System - Mortality Data (CDC WONDER) reported 28,632 deaths due to alcoholic liver disease in the United States, equating to 8.5 deaths per 100,000 population.
Technological Innovations Driving Growth in Liver Disease Therapeutics
Technological advancement is working as a catalyst on liver therapeutics market. New tools help detect liver problems earlier. Non-invasive diagnostic tools or methods are replacing painful biopsies. Imaging techniques have become more accurate and detailed or precise. It allows doctors to see liver damage clearly and quickly. Targeted drug delivery systems are improving treatment outcomes. Medications now reach the liver more effectively. This leads to better results with fewer side effects. Biotechnology is also bringing new therapies to the market. These are designed to treat the disease at its source. Digital health platforms help the doctors to monitor patients remotely. Patients can track symptoms and share the updates in real time. Artificial intelligence (AI) is now used to study disease patterns. Interference of AI is transforming the treatment and diagnosis rapidly. AI also helps doctors choose the best treatment i.e. personalized treatment. Telemedicine is expanding the treatment access to underdeveloped areas. Furthermore, the patients in remote areas can consult liver specialists. These technologies make care faster, safer, and more effective. As innovations continue, the liver disease therapeutics market is expected to grow steadily.
For instance, in May 2025, The Vall d'Hebron Institute of Oncology launched a tool called The GIST that runs on artificial intelligence and has been designed to automate the detection and monitoring of liver tumors. It aims to ultimately increase speed and accuracy in the diagnosis of liver disease.
Hepatitis Dominates the Liver Disease Therapeutics Market
Hepatitis remains the largest segment within the liver disease therapeutics market, and it is due to its high global burden and clinical relevance. Hepatitis C is called a silent epidemic, its severity pushes the infection to chronic conditions like cirrhosis, hepatic failure, or hepatocellular carcinoma. However, the advent of direct-acting antivirals (DAAs), treatment options are becoming increasingly better, creating acceptable cure rates over shorter treatment regimens, generally with better safety profiles. Awareness of screening programs and public health responses are helping in timely diagnosis and eventually timely treatment. Additionally, pharmaceutical companies have made capital investments into further drug development including fixed-dose combinations or pan-genotypic regimens that allow access to treatment and better treatment patterns. With continued efforts from health systems and the pharmaceutical industry, the Hepatitis C segment will continue to be the largest market share of the liver disease therapeutics market in the years to come.
For instance, according to the data published in the Viral Hepatitis Surveillance Report - United States, 2023 reported an estimated 69,000 acute hepatitis C infections and over 101,000 newly diagnosed chronic cases across the United States, along with more than 11,000 related deaths. In another instance, in May 2025, Gilead Sciences, Inc. presented final Phase 3 data on bulevirtide monotherapy at the EASL Congress, showing 36% of chronic hepatitis D patients maintained undetectable viral levels nearly two years after treatment.
North America Dominates the Liver Disease Therapeutics Market
North America continues to dominate the liver disease therapeutics market due to its solid healthcare infrastructure, greater presence of global pharmaceutical companies, and improved public awareness regarding liver health. Not only is the region supporting innovation in therapeutics for hepatitis, fatty liver disease, cirrhosis, and liver cancer, but it is also fostering action in treating liver disease. Supported by a strong pipeline in research and development, both the United States and Canada have a significant portfolio from all the major pharmaceutical companies including the biggest players (e.g. Pfizer, AbbVie, and Johnson & Johnson), which all have a sustained engagement in drug innovation and continuous clinical trials for liver disease. Furthermore, the existing advanced liver disease therapeutics, extensive use of established prescription, over-the-counter medications, and growing access to medication through e-pharmacy, all around the U.S. and Canada, support the liver disease therapeutics market. Additional government health policies and initiatives such as national screening programs, support the promotion of early diagnosis, case detection, and access to timely treatment for patients. The rise in demand for effective therapy options is driven by the high rate of individuals with obesity and problematic alcohol consumption, or those with liver disease because of lifestyle risk factors. Companies in North America frequently engage in mergers and acquisitions and new product launches to strengthen their market position and introduce advanced treatments.
For instance, on November 2024, Gilead Sciences, Inc. presented new research across major liver disease indications at the American Association for the Study of Liver Diseases (AASLD) 2024 meeting.
Impact of U.S. Tariffs on Global Liver Disease Therapeutics Market
Tariffs imposed on imported materials lead to higher costs for the process of manufacturing. As costs increase, they are often passed to the end user in the form of a price increase on treatment.
Tariffs can hinder the consistent and reliable supply of Active Pharmaceutical Ingredients (APIs) from primary manufacturing countries.
Companies may select to work with domestic suppliers or alternate suppliers, which affect time.
Smaller participants may work off of thinner margins, which warrants the potential for competition to lower in the market.
Key Players Landscape and Outlook
The liver disease therapeutics market is experiencing considerable activity from the major pharmaceutical companies in the area with a commitment to establish their position through new products and actions in the area. This includes companies including GSK plc, AbbVie Inc., Pfizer Inc., Johnson & Johnson Services, Inc., and Novartis AG who are funding research, clinical trials, and acquisitions to new treatment option. The focus continues to evolve to targeted therapies, biologics, and advanced medicine that will treat patients with chronic liver conditions including Non-Alcoholic Steatohepatitis (NASH), cirrhosis, and liver cancer. In addition, there are many biotech companies developing new and novel solutions to the competitive landscape. Therefore, the prospects for the market are positive given the increasing patient awareness, growing regulatory pathways favoring innovation, and increasing global need and demand for effective liver disease therapy.
For instance, in July 2025, GSK plc completed the acquisition of efimosfermin, a potential best-in-class specialty medicine aimed at treating and preventing the progression of steatotic liver disease (SLD).
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.